» Articles » PMID: 20184583

The First COL7A1 Mutation Survey in a Large Spanish Dystrophic Epidermolysis Bullosa Cohort: C.6527insC Disclosed As an Unusually Recurrent Mutation

Abstract

Background: Dystrophic epidermolysis bullosa (DEB) is a genodermatosis caused by mutations in COL7A1. The clinical manifestations are highly variable from nail dystrophy to life-threatening blistering, making early molecular diagnosis and prognosis of utmost importance for the affected families. Mutation identification is mandatory for prenatal testing.

Objectives: To conduct the first mutational analysis of COL7A1 in a Spanish cohort, to assess mutation consequences at protein/mRNA level and to establish genotype-phenotype correlations.

Methods: Forty-nine Spanish patients with DEB were studied. Antigen mapping was performed on patient skin biopsies. COL7A1 mutation screening in genomic DNA was performed by polymerase chain reaction (PCR) and direct sequencing. Mutation consequences were determined by reverse transcriptase-PCR.

Results: Eight patients belonged to three unrelated families with dominant DEB. Forty-one were affected with recessive DEB (RDEB). Specifically, 27 displayed the severe generalized subtype, eight the other generalized subtype and six a localized phenotype (two pretibial, three acral and one inversa). Thirty-five mutations were identified, 20 of which are novel. The pathogenic mutation c.6527insC accounted for 46.3% of Spanish RDEB alleles. A consistent genotype-phenotype correlation was established.

Conclusions: Although the COL7A1 database indicates that most DEB mutations are family specific, the pathogenic mutation c.6527insC was highly recurrent in our cohort. This level of recurrence for a single genetic defect has never previously been reported for COL7A1. Our findings are essential to the clinicians caring for patients with DEB in Spain and in the large population of Spanish descendants in Latin America. They also provide geneticists a molecular clue for a priority mutation screening strategy.

Citing Articles

Novel variants impairing Sp1 transcription factor binding in the COL7A1 promoter cause mild cases of recessive dystrophic epidermolysis bullosa.

Pironon N, Gasparyan A, Yubero M, Duchatelet S, Hovhannesyan K, Leclerc-Mercier S Eur J Hum Genet. 2024; 33(3):344-350.

PMID: 39639148 PMC: 11894107. DOI: 10.1038/s41431-024-01717-5.


Skin Microbial Composition and Genetic Mutation Analysis in Precision Medicine for Epidermolysis Bullosa.

Syafarina I, Mazaya M, Indrawati A, Akbar S, Sukowati C, Sadikin R Curr Drug Targets. 2024; 25(6):404-415.

PMID: 38566380 DOI: 10.2174/0113894501290512240327091531.


Clinical and allelic heterogeneity in dystrophic epidermolysis bullosa- lessons from an Indian cohort.

Gupta D, Jayashankar C, Srinivas M, Vishwanathan G, Reddy K, Kubba A PLoS One. 2023; 18(8):e0289558.

PMID: 37556444 PMC: 10411825. DOI: 10.1371/journal.pone.0289558.


Novel variants in LAMA3 and COL7A1 and recurrent variant in KRT5 underlying epidermolysis bullosa in five Chinese families.

Wang R, Sun L, Habulieti X, Liu J, Guo K, Yang X Front Med. 2022; 16(5):808-814.

PMID: 35314946 DOI: 10.1007/s11684-021-0878-x.


Probability of high-risk genetic matching with oocyte and semen donors: complete gene analysis or genotyping test?.

Molina Romero M, Yoldi Chaure A, Ganan Parra M, Navas Bastida P, Del Pico Sanchez J, Vaquero Arguelles A J Assist Reprod Genet. 2022; 39(2):341-355.

PMID: 35091964 PMC: 8956772. DOI: 10.1007/s10815-021-02381-0.